A world-first dengue vaccination programme in the Philippines that was suspended over safety concerns will not cause anyone who was immunised to die, drug manufacturer Sanofi and local authorities said on Monday
The Philippines has suspended the sale and distribution of Sanofi’s dengue vaccine, authorities said on Tuesday, after the French pharmaceutical giant last week warned it could worsen symptoms for people who had not previously been infected.
Machine learning technologies have already made huge strides in supporting the efforts of pharmaceutical companies in developing personalized medicines and novel biomarkers. This has been found to be helpful, notably for understanding the efficacy of prophylactic vaccines used for combating infectious diseases.
Prospects for Takeda’s dengue vaccine just turned brighter following fresh data from the company’s Phase II trial. For Takeda, the data is likely welcome considering the company already has a massive pivotal trial underway for the vaccine. For competitor Sanofi … perhaps not so welcome.
Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
Sanofi announced that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.
Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
Sanofi is to buy private US vaccines biotech Protein Sciences in a deal valued at up to $750 million, in a move to bolster its vaccines portfolio.
Don Tracy, Associate Editor Dupixent has previously been approved for adults with chronic rhinosinusitis with nasal polyposis whose condition is inadequately controlled. Regeneron and Sanofi announced that the FDA has granted Priority Review to their supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 years who have chronic rhinosinusitis with nasal polyposis (CRSwNP) and whose condition is inadequately controlled. With the treatment already approved for adults with CRSwNP, the FDA is expected to make a final decision on the sBLA for the expanded indication by September 15, 2024.1 According to the companies, the application is supported by efficacy data from SINUS-24 and SINUS-52, two trials that showed major improvements in nasal congestion/obstruction severity, nasal polyp size, sense of smell, and a reduction in the need for systemic corticosteroids or surgery. In 2019, Regeneron first released the results of both trials, ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.